Algorae Pharmaceuticals Ltd (1AI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Algorae Pharmaceuticals Ltd (1AI) has a cash flow conversion efficiency ratio of -0.327x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-618.21K ≈ $-437.42K USD) by net assets (AU$1.89 Million ≈ $1.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Algorae Pharmaceuticals Ltd stock valuation for the company's overall valuation and market capitalisation.
Algorae Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Algorae Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Algorae Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Algorae Pharmaceuticals Ltd ranked by their cash flow conversion efficiency. Explore Algorae Pharmaceuticals Ltd cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AHB Holdings Bhd
KLSE:7315
|
-0.046x |
|
OpTeam S.A.
WAR:OPM
|
-0.102x |
|
Raspberry Pi Holdings PLC
LSE:RPI
|
0.028x |
|
GENOMTEC S.A. ZY -10
F:4VI
|
N/A |
|
Quality Concrete Holdings Bhd
KLSE:7544
|
-0.059x |
|
Emova Group SA
PA:ALEMV
|
0.190x |
|
Falcon Power Co Ltd
TW:1516
|
0.032x |
|
Majuperak Holdings Bhd
KLSE:8141
|
-0.009x |
Annual Cash Flow Conversion Efficiency for Algorae Pharmaceuticals Ltd (2004–2025)
The table below shows the annual cash flow conversion efficiency of Algorae Pharmaceuticals Ltd from 2004 to 2025. View 1AI share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$2.23 Million ≈ $1.58 Million |
AU$-785.25K ≈ $-555.61K |
-0.352x | -22.91% |
| 2024-06-30 | AU$5.31 Million ≈ $3.76 Million |
AU$-1.52 Million ≈ $-1.08 Million |
-0.287x | +16.52% |
| 2023-06-30 | AU$5.78 Million ≈ $4.09 Million |
AU$-1.99 Million ≈ $-1.41 Million |
-0.343x | +32.16% |
| 2022-06-30 | AU$4.03 Million ≈ $2.85 Million |
AU$-2.04 Million ≈ $-1.44 Million |
-0.506x | +52.31% |
| 2021-06-30 | AU$1.38 Million ≈ $974.40K |
AU$-1.46 Million ≈ $-1.03 Million |
-1.061x | +1.77% |
| 2020-06-30 | AU$2.88 Million ≈ $2.04 Million |
AU$-3.11 Million ≈ $-2.20 Million |
-1.080x | -124.63% |
| 2019-06-30 | AU$4.14 Million ≈ $2.93 Million |
AU$-1.99 Million ≈ $-1.41 Million |
-0.481x | +3.88% |
| 2018-06-30 | AU$7.14 Million ≈ $5.05 Million |
AU$-3.57 Million ≈ $-2.53 Million |
-0.500x | -11.63% |
| 2017-06-30 | AU$7.52 Million ≈ $5.32 Million |
AU$-3.37 Million ≈ $-2.38 Million |
-0.448x | +19.40% |
| 2016-06-30 | AU$5.68 Million ≈ $4.02 Million |
AU$-3.16 Million ≈ $-2.23 Million |
-0.556x | +20.52% |
| 2015-06-30 | AU$5.13 Million ≈ $3.63 Million |
AU$-3.59 Million ≈ $-2.54 Million |
-0.700x | -7056.25% |
| 2014-06-30 | AU$8.43 Million ≈ $5.97 Million |
AU$-82.44K ≈ $-58.33K |
-0.010x | -109.69% |
| 2013-06-30 | AU$13.25 Million ≈ $9.38 Million |
AU$1.34 Million ≈ $946.01K |
0.101x | +158.23% |
| 2012-06-30 | AU$14.35 Million ≈ $10.16 Million |
AU$-2.49 Million ≈ $-1.76 Million |
-0.173x | +79.53% |
| 2011-06-30 | AU$6.76 Million ≈ $4.78 Million |
AU$-5.72 Million ≈ $-4.05 Million |
-0.847x | +9.92% |
| 2010-06-30 | AU$6.24 Million ≈ $4.41 Million |
AU$-5.86 Million ≈ $-4.15 Million |
-0.940x | +8.93% |
| 2009-06-30 | AU$5.53 Million ≈ $3.91 Million |
AU$-5.70 Million ≈ $-4.04 Million |
-1.032x | -111.67% |
| 2008-06-30 | AU$11.48 Million ≈ $8.13 Million |
AU$-5.60 Million ≈ $-3.96 Million |
-0.487x | +87.66% |
| 2007-06-30 | AU$1.40 Million ≈ $991.53K |
AU$-5.54 Million ≈ $-3.92 Million |
-3.951x | -7.34% |
| 2006-06-30 | AU$1.80 Million ≈ $1.27 Million |
AU$-6.61 Million ≈ $-4.68 Million |
-3.681x | -89.36% |
| 2005-06-30 | AU$3.14 Million ≈ $2.22 Million |
AU$-6.09 Million ≈ $-4.31 Million |
-1.944x | -302.54% |
| 2004-06-30 | AU$-1.33 Million ≈ $-937.82K |
AU$-1.27 Million ≈ $-900.02K |
0.960x | -- |
About Algorae Pharmaceuticals Ltd
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up … Read more